Megirian R, Astry C L, Spoor R P, Loose L
Cancer Treat Rep. 1980 Aug-Sep;64(8-9):915-20.
Single and multiple doses of Corynebacterium parvum ranging from 0.01 to 60 mg/kg as the total dose were tested at selected times against 10(6) P388 leukemia cells inoculated ip in BDF1 mice. The minimum dose needed for maximum protection was determined according to the ability of the treatment to produce an increase in the lifespan (ILS) of mice. The ip dose required after transplant for significant ILS was 40 mg/kg as the total dose. The administration of a single dose 2 days prior to implant produced maximum antitumor effects at 1 mg/kg, with all other doses above and below this level being significantly less effective. Protection was achieved before implant, with the following maximum ILS recorded for each dose and time: 1 mg/kg on Day -2 = 110%; 60 mg/kg on Day -5 = 70%; 10 mg/kg on Day -2 = 50%; and 0.1 and 0.01 mg/kg on either Day -2 or Day -5 = 25%-30%. Cytotoxicity studies demonstrated that 51Cr release after 1 mg/kg was more rapid in onset (peaking on Day 3 after treatment) than after 60 mg/kg (peaking on Day 5 after treatment). It was concluded that the proper adjustment of the dose and time of administration of C. parvum prior to tumor transplant enhanced antitumor activity of this immunopotentiator. Considerably higher doses were required after transplant for the desired effects to be achieved. The cytotoxicity studies demonstrated differences in tumor cell-killing which were dose-related and may be a contributing factor in the dose and time-related antitumor effects of C. parvum.
以0.01至60mg/kg的总剂量,对单剂量和多剂量的短小棒状杆菌进行了测试,测试时间选在接种10(6)个腹腔注射的P388白血病细胞的BDF1小鼠身上。根据治疗对小鼠寿命延长(ILS)的促进能力,确定了实现最大保护所需的最小剂量。移植后产生显著ILS所需的腹腔注射剂量为40mg/kg总剂量。在植入前2天给予单剂量,在1mg/kg时产生最大抗肿瘤效果,高于和低于该水平的所有其他剂量效果均明显较差。在植入前实现了保护,每个剂量和时间记录的最大ILS如下:第-2天1mg/kg = 110%;第-5天60mg/kg = 70%;第-2天10mg/kg = 50%;第-2天或第-5天0.1和0.01mg/kg = 25%-30%。细胞毒性研究表明,1mg/kg后51Cr释放的起效速度(在治疗后第3天达到峰值)比60mg/kg后(在治疗后第5天达到峰值)更快。得出的结论是,在肿瘤移植前适当调整短小棒状杆菌的剂量和给药时间可增强这种免疫增强剂的抗肿瘤活性。移植后需要相当高的剂量才能达到预期效果。细胞毒性研究表明,肿瘤细胞杀伤存在剂量相关差异,这可能是短小棒状杆菌剂量和时间相关抗肿瘤作用的一个促成因素。